SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has acquired world-wide rights to a patent submission entitled, “De-repression of anticancer immunity through extracorporeal removal of microvesicular particles.” Under the patent, assigned to Aethlon Medical by London Health Science Center Research Inc., the Aethlon HemopurifierTM would address a significant unmet clinical need in cancer therapy by reducing the presence of tumor-secreted microvesicles that inhibit the immune system from responding in cancer patients.
